Pharmaceuticals
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131 I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substan...
2025-04-16 06:45
2447
Open nominations for the BIAL Award in Biomedicine 2025 with an increased amount to €350,000
Created to distinguish the most remarkable scientific discoveries in the biomedical field, this international award has been granted a growing reputation as a prelude to the Nobel Prize since it has distinguished in a former edition two authors subsequently honoured with the Nobel Prize in Medic...
2025-04-15 15:00
2311
Wang Qunbin: Leveraging Innovation and Global Operational Strengths to Contribute "Fosun Power" to the Development of Hainan Free Trade Port
HONG KONG and SHANGHAI, April 15, 2025 /PRNewswire/ -- On April 14, the 2025 Hainan Free Trade Port Global Investment Promotion Conference was held inHaikou . Jointly hosted by the People's Government ofHainan Province and the Ministry of Commerce, the conference is one of the key events in the 20...
2025-04-15 12:05
3364
Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment o...
2025-04-12 17:20
4344
Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved
SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with mod...
2025-04-10 19:23
3977
Medtec Southeast Asia 2025 - The Southeast Asia's Premier Medical Device Design & Manufacturing Exhibition Debuts in Malaysia
KUALA LUMPUR, Malaysia, April 10, 2025 /PRNewswire/ -- Informa Markets announces the launch ofMedtec Southeast Asia 2025, the premier medical device design and manufacturing exhibition inSoutheast Asia, making its debut in Malaysia. The inaugural Medtec Southeast Asia 2025 exhibition will take p...
2025-04-10 16:58
4319
Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation
- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation systemexpected to cover the entire PCR workforce, from sample pre-processing to result analysis. - Designed for 24-hour, seven-days-a-week, unattended, CURECA™ reflects the company's mission to ...
2025-04-09 21:00
3392
Asia Health & Medlab Asia Rebrands to WHX and WHX Labs in Kuala Lumpur and Bangkok
KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ -- The global event organisation leader Informa Markets revealed a major rebranding of its healthcare exhibitions portfolio which resulted in the formation of WHX (World Health Expo). WHX rebrands its healthcare events acrossSoutheast Asia to WHX...
2025-04-09 19:49
3272
Alpro Pharmacy Now Offers Free AIA Vitality Health Check to Support Early Disease Detection
KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ -- Millions of Malaysians are at risk of serious health complications due to undiagnosed and unmanaged non-communicable diseases (NCDs), such as diabetes, hypertension, high cholesterol, and obesity. According to the National Health and Morbidity...
2025-04-09 10:00
2808
Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer
* This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development. * The partnership will advance the development of first-in-class precision therapeutics for multiple cancer ty...
2025-04-08 09:00
2641
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectivelydeliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and n...
2025-04-07 08:34
4720
George Clinical Rebrands as Emerald Clinical Trials
New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials SINGAPORE, April 7, 2025 /PRNewswire/ -- George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to becomeEmerald ...
2025-04-07 08:00
2594
Telix Appoints Paul Schaffer as Chief Technology Officer
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr.Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has...
2025-04-07 07:09
3943
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identific...
2025-04-03 07:45
4614
LBB Specialties Partners with Kerry Group to Launch Pharmaceutical Lactose to the Life Sciences Market
NORWALK, Conn., April 3, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredient distribution in North America, is pleased to announce a new partnership with Kerry Group, a world leading taste and nutrition partner for the food, beverage, and pharmaceutical mark...
2025-04-03 01:30
2664
Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit
HONG KONG and SHANGHAI, April 2, 2025 /PRNewswire/ -- On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group") held its 2024 annual results presentation inShanghai. The results presentation was attended b...
2025-04-02 13:51
4955
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
MELBOURNE, Australia, April 2, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89 Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma...
2025-04-02 03:30
2832
Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer's Dementia
TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and Welfare as a new drug, indicated for suppression of progressio...
2025-03-31 21:35
2911
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation of small molecule ASC30 demonstrated potentially ...
2025-03-31 19:00
2502
Clinical Study demonstrates Kerry Group Supplement Solution Sensoril® Ashwagandha Supports Quality of Life for Post-Menopausal Women
Sensoril® Ashwagandha is among Kerry's portfolio of solutions tailored to meet
women's unique health needs
SINGAPORE, March 31, 2025 /PRNewswire/ -- Sensoril® ashwagandha
2025-03-31 17:30
2914
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
7776
